|
🐜
|
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
12 auth.
K. Blackwell,
H. Burstein,
A. Storniolo,
H. Rugo,
G. Sledge,
M. Koehler,
...
C. Ellis,
M. Casey,
S. Vukelja,
J. Bischoff,
J. Baselga,
J. O’Shaughnessy
|
9 |
2010 |
9
🐜
|
|
🐜
|
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
12 auth.
K. Blackwell,
H. Burstein,
A. Storniolo,
H. Rugo,
G. Sledge,
G. Aktan,
...
C. Ellis,
A. Florance,
S. Vukelja,
J. Bischoff,
J. Baselga,
J. O’Shaughnessy
|
9 |
2012 |
9
🐜
|
|
🐜
|
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
15 auth.
R. Salgado,
C. Denkert,
C. Campbell,
P. Savas,
P. Nuciforo,
C. Aura,
E. de Azambuja,
H. Eidtmann,
C. Ellis,
J. Baselga,
...
M. Piccart-Gebhart,
S. Michiels,
I. Bradbury,
C. Sotiriou,
S. Loi
|
9 |
2015 |
9
🐜
|
|
🐜
|
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.
21 auth.
I. Majewski,
P. Nuciforo,
L. Mittempergher,
A. Bosma,
H. Eidtmann,
E. Holmes,
C. Sotiriou,
D. Fumagalli,
J. Jiménez,
C. Aura,
...
L. Prudkin,
Maria Carmen Díaz-Delgado,
L. de la Peña,
S. Loi,
C. Ellis,
N. Schultz,
E. de Azambuja,
N. Harbeck,
M. Piccart-Gebhart,
R. Bernards,
J. Baselga
|
7 |
2015 |
7
🐜
|
|
🐜
|
Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor
18 auth.
M. Scaltriti,
S. Chandarlapaty,
L. Prudkin,
C. Aura,
J. Jiménez,
P. Angelini,
Gertrudis Sánchez,
M. Guzman,
J. Parra,
C. Ellis,
...
R. Gagnon,
M. Koehler,
H. Gómez,
C. Geyer,
D. Cameron,
J. Arribas,
N. Rosen,
J. Baselga
|
7 |
2010 |
7
🐜
|
|
🐜
|
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
12 auth.
A. Prat,
M. Cheang,
P. Galván,
P. Nuciforo,
L. Paré,
B. Adamo,
...
M. Muñoz,
M. Viladot,
M. Press,
R. Gagnon,
C. Ellis,
S. Johnston
|
6 |
2016 |
6
🐜
|
|
🐜
|
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies
18 auth.
M. Toi,
H. Iwata,
Y. Fujiwara,
Yoshinori Ito,
S. Nakamura,
Y. Tokuda,
T. Taguchi,
Y. Rai,
K. Aogi,
T. Arai,
...
J. Watanabe,
T. Wakamatsu,
K. Katsura,
C. Ellis,
R. Gagnon,
K. Allen,
Y. Sasaki,
S. Takashima
|
6 |
2009 |
6
🐜
|
|
🐜
|
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
16 auth.
V. Guarneri,
M. Dieci,
A. Frassoldati,
A. Maiorana,
G. Ficarra,
S. Bettelli,
E. Tagliafico,
S. Bicciato,
D. Generali,
K. Cagossi,
...
G. Bisagni,
S. Sarti,
A. Musolino,
C. Ellis,
R. Crescenzo,
P. Conte
|
6 |
2015 |
6
🐜
|
|
🐜
|
Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study.
25 auth.
K. Harrington,
S. Temam,
H. Mehanna,
A. D'cruz,
M. Jain,
Ida D'Onofrio,
G. Manikhas,
Z. Horváth,
Yan Sun,
S. Dietzsch,
P. Dubinsky,
P. Holečková,
I. El‐Hariry,
N. Franklin,
N. Biswas-Baldwin,
...
P. Legenne,
P. Wissel,
Thelma Netherway,
J. Farrell,
C. Ellis,
J. Wang-silvanto,
M. Amonkar,
Nazma Ahmed,
S. Santillana,
J. Bourhis
|
6 |
2015 |
6
🐜
|
|
🐜
|
Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay
17 auth.
A. Prat,
P. Galván,
B. Jímenez,
Wesley Buckingham,
H. A. Jeiranian,
C. Schaper,
M. Vidal,
M. Álvarez,
S. Díaz,
C. Ellis,
...
P. Nuciforo,
S. Ferree,
N. Ribelles,
B. Adamo,
S. Ramón y. Cajal,
V. Peg,
E. Alba
|
6 |
2015 |
6
🐜
|
|
🐜
|
High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
22 auth.
M. Scaltriti,
P. Nuciforo,
I. Bradbury,
J. Sperinde,
D. Agbor-tarh,
C. Campbell,
A. Chenna,
J. Winslow,
V. Serra,
J. Parra,
...
L. Prudkin,
J. Jiménez,
C. Aura,
N. Harbeck,
L. Pusztai,
C. Ellis,
H. Eidtmann,
J. Arribas,
J. Cortés,
E. de Azambuja,
M. Piccart,
J. Baselga
|
6 |
2014 |
6
🐜
|
